News
In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...
1h
Zacks Investment Research on MSNNVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...
Thousands taking Mounjaro privately are inundating GP surgeries - clogging phone lines, exacerbating the 8am scramble for ...
1h
inews.co.uk on MSNGPs swamped by requests for NHS Mounjaro – but hardly anyone qualifiesThousands taking Mounjaro privately are inundating GP surgeries - clogging phone lines, exacerbating the 8am scramble for ...
GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have ...
Health news includes a cyberattack affecting patient care in London, Walgreens' financial success amid strategic changes, ...
Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...
The collaboration, set to begin on 1 July, will see Novo Nordisk team up with the telehealth company to offer Wegovy to ...
Spain is investigating Novo Nordisk over concerns it may be indirectly marketing its weight loss drugs. Euronews Health spoke ...
The Vanguard Growth ETF ( VUG 0.85%) doesn't just beat the market -- it demolishes it. A $10,000 investment at its 2004 ...
Eli Lillys Mounjaro KwikPen gains approval in India, targeting diabetes and obesity with its dual-action formula for weight ...
Apollo HealthCo clocked a revenue of ₹9,093 crore in FY25, growing 16% year-on-year. The platform delivered three successive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results